Transition Therapeutics Announces Results of Clinical Study of Type 2 Diabetes Drug Candidate TT-401

Transition Therapeutics Announces Results of Clinical Study of Type 2 Diabetes
                            Drug Candidate TT-401

PR Newswire

TORONTO, April 30, 2013

TORONTO,  April  30,   2013  /PRNewswire/  -   Transition  Therapeutics   Inc. 
("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced the results
of a five-week proof of  concept clinical study of  TT-401 in type 2  diabetic 
and  obese  non-diabetic  subjects.In   the  study,  TT-401  a   once-weekly 
administered  peptide,  demonstrated  significant  improvements  in   glycemic 
control and reductions in body weight.

The study enrolled diabetic  patients at five  dosing levels and  non-diabetic 
obese patients at one dose level. All dosing cohorts received five doses over
a five week period. Diabetic patients were on stable doses of  metformin.At 
the end of the treatment period, TT-401-treated patients in the three  highest 
dose groups experienced statistically  significant reductions in mean  fasting 
plasma glucose relative to placebo.

Statistically significant  mean body  weight  reduction relative  to  baseline 
occurred in the three highest dose groups.A similar reduction in body weight
was also observed in the obese non-diabetic cohort.

TT-401 demonstrated an acceptable safety and tolerability profile at all doses
evaluated in  diabetic  and  non-diabetic obese  subjects.  The  most  common 
adverse event noted in the study was decreased appetite.Some subjects in the
highest three  dose groups  experienced mild  nausea and  vomiting, which  are 
consistent  with  studies  of  other  GLP-1  agonist  drug  candidates.   The 
pharmacokinetic profile, assessed  over the  five week  study, demonstrated  a 
half-life consistent with once-weekly dosing.

"We are very pleased with the proof of concept data from this study. This  new 
dual agonist  that  targets  GLP-1  and a  second  metabolic  mechanism  shows 
promising effects  on  weight loss  and  glycemic control  and  could  provide 
broader therapeutic  benefit to  patients with  type 2  diabetes. These  data 
support a clear development path forward to a larger Phase 2 efficacy study of
TT-401," said Dr. Aleksandra Pastrak, Vice President, Clinical Development and
Medical Officer of Transition.

TT-401 is a dual agonist of  the GLP-1 (Glucagon-Like Peptide-1) and  glucagon 
receptors.  In  March   2010,  Transition   entered  into   a  licensing   and 
collaboration agreement with Eli Lilly and Company, where Transition  acquired 
the rights to a series of pre-clinical compounds from Lilly, including  TT-401 
for the treatment of type 2 diabetes.

About Transition

Transition is a biopharmaceutical  company, developing novel therapeutics  for 
disease indications with large markets. The Company's lead CNS drug  candidate 
is ELND005 for  the treatment  of Alzheimer's disease  and bipolar  disorder. 
Transition's lead metabolic drug candidate is TT-401 for the treatment of type
2 diabetes and accompanying  obesity. The Company's shares  are listed on  the 
NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol
"TTH".  For   additional  information   about   the  Company,   please   visit 
www.transitiontherapeutics.com.

Notice to  Readers: Information  contained  in our  press releases  should  be 
considered accurate only as of the date  of the release and may be  superseded 
by more recent information we have disclosed in later press releases,  filings 
with the OSC, SEC or otherwise. Except for historical information, this  press 
release may  contain  forward-looking statements,  relating  to  expectations, 
plans or prospects  for Transition, including  conducting clinical trials  and 
potential efficacy  of  its products.  These  statements are  based  upon  the 
current expectations and beliefs of Transition's management and are subject to
certain risks  and uncertainties  that could  cause actual  results to  differ 
materially from those described in the forward-looking statements. These risks
and uncertainties include  factors beyond  Transition's control  and the  risk 
factors and other  cautionary statements discussed  in Transition's  quarterly 
and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.

Contact:

For further information on Transition, visitwww.transitiontherapeutics.com or
contact:
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223
tcruz@transitiontherapeutics.com